Gland Pharma Receives USFDA Approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC)

Gland Pharma Limited, a generic injectable & ophthalmic-focused pharmaceutical company, has received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application filed for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC). The Product is therapeutically equivalent to the reference listed drug (RLD), Pataday Once Daily Relief, 0.7%, of Alcon Laboratories Inc. This Product is indicated for the treatment of ocular itching associated with allergic conjunctivitis. Gland Pharma, established in 1978, has grown over the years to become one of the largest injectable-focused companies with a global footprint across 60 countries. It operates primarily under a business-to-business (B2B) model and has an excellent track record in developing, manufacturing, and marketing sterile injectables.